Human beta chains form beta-gamma intermediates and join pre-existing alpha-gamma intermediates during fibrinogen assembly. The experiments express human chains in BHK recipients and resolve assembled complexes by immunoprecipitation and two-dimensional electrophoresis; human hepatoma cells provide additional context. This establishes structural work by the beta chain, beyond a phenotype of protein loss (PMID:8910396(https://pubmed.ncbi.nlm.nih.gov/8910396/), Figures 1–5). Human plasma fibrinogen crystallography directly resolves beta-chain-containing domains and coiled coils. Crystal packing is not treated as an independent polymerization or mechanical assay (PMID:19296670(https://pubmed.ncbi.nlm.nih.gov/19296670/), printed pages 3878–3882).
The chain distinction matters for platelet aggregation. Intact human fibrinogen was active, whereas the reduced/carboxymethylated beta-chain preparation was inactive in the original comparison; alpha and gamma preparations were positive. The retained non-core process describes beta chain within the structural ligand complex, not an autonomous beta-chain platelet agonist (PMID:6281794(https://pubmed.ncbi.nlm.nih.gov/6281794/), Table 1 and Figure 1). The separate plasminogen-activation and fibrinolysis annotations remain uncertain: the original variant experiment is incompletely accessible, and alpha-C oligomer experiments cannot establish a beta-specific cofactor mechanism (PMID:16846481(https://pubmed.ncbi.nlm.nih.gov/16846481/)).
Endothelial adhesion, ERK activation, survival, vasoconstriction and secretion studies test assembled human fibrinogen or mixed-chain fragments. Gamma-chain recognition controls and rat recipient preparations are retained where applicable. These results support contextual complex participation; they do not establish an autonomous beta-chain receptor-binding site, kinase, secretion apparatus or contractile activity (PMID:10903502(https://pubmed.ncbi.nlm.nih.gov/10903502/), adhesion Table 1 and survival Results; PMID:9182580(https://pubmed.ncbi.nlm.nih.gov/9182580/), Figure 1B; PMID:15739255(https://pubmed.ncbi.nlm.nih.gov/15739255/), Figures 6–8; PMID:19193866(https://pubmed.ncbi.nlm.nih.gov/19193866/), Figures 1–4).
Clusterin-associated human plasma complexes contain a mass-spectrometrically identified fibrinogen beta chain, with chain immunoblots and size-exclusion/ELISA corroboration. This supports client binding to a chaperone, not FGB chaperone activity or a purified binary affinity. The paper's control-storage temperature differs between Methods and a figure caption; no quantitative in-vivo extrapolation is made (PMID:19996109(https://pmc.ncbi.nlm.nih.gov/articles/PMC2823492/), Table 1 and Figures 4–6). The separate tagged core-protein interaction is kept as a non-core association and is not promoted to intact-virion binding (PMID:20162731(https://pubmed.ncbi.nlm.nih.gov/20162731/), Figure 2).
Exact protein records were recovered for human colon/liver ECM proteomics, breast/omentum proteomics and cerebrospinal-fluid vesicle fractions. They do not identify free fibrinopeptide B, a unique natural splice, or vesicle topology. Five other proteomic sources retain unresolved target/sample joins; an inaccessible table is not evidence of absence. The RCA structural classification is distinguished from an unresolved HDA target-context assertion (source guide).
The official P02675 record distinguishes signal peptide 1–30, fibrinopeptide B 31–44 and chain 45–491. All imported source contexts use the parent product; none is converted to a cleavage product. The original variant abstract for PMID:18676163 concerns alphaCys45Phe and gammaAsn345Ser, not an FGB variant. Its generic complex annotation remains supported independently by chain-resolved assembly.
The genuine provider attempt produced no report. Its private traces were not inspected for a failure cause, and no provider-branded replacement text was authored. This journal records manual primary-source assessment. No publication quotations or new GO assertions were added.